Additionally, GCM2 is frequently hypermethylated across both histological subtypes—such as invasive ductal carcinoma and invasive lobular carcinoma—and molecular subtypes, including luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (Fig. S2). Here, GCM2 is linked to triple-negative breast carcinoma.